Secondary Outcomes Days of MV: Four RCTs, reporting data on 989 patients, showed a trend in favor of treatment with melatonin with a lower number of days spent on MV (MD −2.80 (95%CI −6.06, 0.47), p = 0.09; I 2 = 94%; Supplementary Materials ).
The total RV scar area showed a trend towards an association with VA: the mean RV scar area was 111 cm 2 in patients with VA and 83 cm 2 in those without VA ( p = 0.09), and the percentage of the RV scar was 37% in those with VA and 28% in those without VA ( p = 0.05).
In contrast, maximal respiration showed a trend toward an increase ( p = 0.09), and proton leak was significantly elevated ( Fig. 5G,H ).
The analysis also showed a trend toward a possible association between persistent headache and depressive symptoms (univariate analysis with an OR of 8.000 [range: 0.725–88.226]; p = 0.090).
Airways resistance showed a trend of increase in children from urbanised areas compared to all the others (p = 0.09) while FEV1 tended to increase in children from rural neighbourhoods as compared to those from the urbanised areas (p = 0.08).
Patients with diffuse slow wave activity showed a trend to have higher glucose levels as compared to patients with focal slow wave activity (698.7 ± 52.3 vs. 553.2 ± 213.5 mg/dL; p = 0.09).
For Model 2 a sensitivity analysis of biopsy type (Table 3 ) showed that first TCMR on a for‐cause biopsy was a significant correlate of death‐censored and all‐cause graft loss, while first TCMR on a surveillance biopsy showed a trend ( p = .09) toward an increased risk of death‐censored allograft loss and no significant association with all‐cause allograft loss after adjustment for baseline covariates, DGF, and ABMR.
A similar trend was also observed in Tempus OS that IFNγ scores showed a trend of favorable OS outcomes only in PD-L1 high subgroups (HR = 0.63, P value = 0.09 for PD-L1 ≥50% vs.
endoscopic) and arytenoid removal showed a trend toward a higher risk ( p = 0.09) of temporary and permanent tracheostomy, respectively.
Vice versa, patients with AF recurrence showed a trend towards a higher median AHI value, 14.7 (IQR, 7.5–28.0) versus 10.6 (IQR, 6.6–16.5), P = 0.09 ( Fig. 3 ).
Patients with cutaneous manifestations showed a trend towards lower frequency of lung damage ( p = 0.09).
At 16 and 24 weeks, O-CAF rats also showed a trend to greater fat mass than O-C rats ( p = 0.09, two-way ANOVA), but no significant differences were found between both groups.
The intervention also showed a trend toward statistical significance in abstinence knowledge scores (0.129, P =.09).
22-26 Furthermore, mutational profiling of pretreatment biopsy samples with matched gene expression data showed a trend toward more non-CR patients in the TP53 mutant group ( P = .09) ( Figure 6G ).
In the jejunum, APN activity per unit length was significantly higher in the LP group than in the EF group and showed a trend toward being higher than in the AC group ( p = 0.09) ( Figure 1 C).
Urinary output showed a trend to be higher in RDS versus TTN ( P = 0.09); there was no difference of TFI, nor minimal serum sodium concentration between the two groups (Table 2 ).
Correlations between fPDRP NS expression and motor ratings were also significant in the North Shore PD sample (r = 0.61, p < 0.01; Pearson correlation) and showed a trend in the Cologne dataset (r = 0.24, p = 0.09). 3.2.
Maternal pre-pregnancy BMI showed a trend for an inverse correlation with placental EtP concentration (r = -0.12, p = 0.090) ( Fig. 3 A) and was significantly inversely correlated with cord blood GGT activity (r = -0.14, p = 0. 045) ( Fig. 3 B).
Furthermore, they showed a trend for lower Apo-B:Apo-A1 ratio ( p = 0.090) and lower IL-6 ( p = 0.065). 3.4.
Targeted therapy before the presence of BM showed a trend towards significantly worse IPFS in univariate analysis but had a very wide confidence interval (HR 3.15; 95% CI: 0.81–15.23; p = 0.09).
The addition of elotuzumab to Vd in a phase II clinical trial showed a trend towards increased OS and PFS (median, 9.7 vs. 6.9 months, p = 0.09) but did not reach statistical significance [ 107 ].
For vasodilators/nitrates, used by 11 participants (6 cases, 5 controls), hsa-miR-126-3p showed a trend toward higher expression in users (median 119.5) compared to non-users (median 29.0, p = 0.09).
[ 14 ] showed a trend (p = 0.09) for carbohydrate consumption to attenuate the exercise induced increase in gene expression for GLUT4 under ambient conditions.
VMAT plans showed a trend towards higher MU with a median difference between 18% and 24% (p ≤ 0.09).
Results showed a trend for a block*group interaction [ F (3.62, 535.08) = 2.06, p = 0.09].